It is well known that the evolution of diseases makes classical drugs ineffective. A viable strategy to overcome problems such as resistance, side effects, and microorganisms’ ability to develop biofilms is provided by complexes, especially by those bearing transition metal ions and multidentate ligands. Several species of this type were tested and proved to have valuable antitumor, antimicrobial, anti-inflammatory, anti-infective, or antiparasitic activity both in vitro and in vivo. Important aspects that need to be clarified in the development of these compounds as drugs are their interactions with serum and cytoplasmic peptides, as well as with the target sites, which most often are DNA and enzymes. This Special Issue will cover the aspects concerning the design, synthesis, characterization, and in vitro or in vivo assay of various complexes as potential biological active species.
"New Trends in Developing Complexes as Biological Active Species"
Maura Pellei;Carlo Santini
2021-01-01
Abstract
It is well known that the evolution of diseases makes classical drugs ineffective. A viable strategy to overcome problems such as resistance, side effects, and microorganisms’ ability to develop biofilms is provided by complexes, especially by those bearing transition metal ions and multidentate ligands. Several species of this type were tested and proved to have valuable antitumor, antimicrobial, anti-inflammatory, anti-infective, or antiparasitic activity both in vitro and in vivo. Important aspects that need to be clarified in the development of these compounds as drugs are their interactions with serum and cytoplasmic peptides, as well as with the target sites, which most often are DNA and enzymes. This Special Issue will cover the aspects concerning the design, synthesis, characterization, and in vitro or in vivo assay of various complexes as potential biological active species.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
